Sugi Predict

Sugi Predict / Compounds / SCHEMBL571151

SCHEMBL571151

SCHEMBL571151

Oc1ccc(C2COc3cc(O)c(O)cc3C2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ ALOX12 P18054 7/20 1.00
▸ ALOX15 P16050 7/20 1.00
▸ ALOX15B O15296 3/20 1.00
▸ ESR2 Q92731 5/20 0.74
▸ ESR1 P03372 3/20 0.74
▸ TTR P02766 1/20 0.74
▸ RARA P10276 1/20 0.39
▸ RARB P10826 1/20 0.39
▸ RARG P13631 1/20 0.39
▸ KDM1A O60341 1/20 0.39
▸ KDM4E B2RXH2 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ CYP3A4 P08684 1/20 0.38
▸ MAPT P10636 1/20 0.38
▸ MAPK1 P28482 1/20 0.38
▸ HSD17B10 Q99714 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10563269 0.88 ALOX12 (0.78) ALOX12ALOX15ALOX15BESR2ESR1
SCHEMBL29525502 0.88 ALOX12 (0.78) ALOX12ALOX15ALOX15BESR2ESR1
SCHEMBL10563899 0.88 ALOX12 (0.78) ALOX12ALOX15ALOX15BESR2ESR1
SCHEMBL10559567 0.88 ALOX12 (0.78) ALOX12ALOX15ALOX15BESR2ESR1
SCHEMBL10562687 0.87 ALOX15 (0.77) ALOX12ALOX15ALOX15BESR2ESR1
Aus-131 SCHEMBL43648 0.85 ESR2 (1.00) ALOX12ALOX15ALOX15BESR2ESR1
Aus-131 SCHEMBL29467332 0.85 ESR2 (1.00) ALOX12ALOX15ALOX15BESR2ESR1
Aus-131 SCHEMBL2002128 0.85 ESR2 (1.00) ALOX12ALOX15ALOX15BESR2ESR1
Aus-131 SCHEMBL677723 0.85 ESR2 (1.00) ALOX12ALOX15ALOX15BESR2ESR1
Aus-131 SCHEMBL43647 0.85 ESR2 (1.00) ALOX12ALOX15ALOX15BESR2ESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150150770-A1 METHODS OF TREATING SKIN TRACIE MARTYN INTERNATIONAL INC (US) 2015-06-04 — — US disclosed
US-20140234271-A1 COMPOSITIONS FOR PROLIFERATION OF CELLS AND RELATED METHODS THE HOSPITAL FOR SICK CHILDREN (CA) 2014-08-21 — — US disclosed
US-8748177-B2 Compositions for proliferation of cells and related methods THE HOSPITAL FOR SICK CHILDREN (CA) 2014-06-10 — — US disclosed
US-20140155961-A1 METHODS OF TREATING SKIN Tracie Martyn International, Inc. (US) 2014-06-05 — — US disclosed
EP-2598150-A2 COMPOSITIONS FOR PROLIFERATION OF CELLS AND RELATED METHODS The Hospital For Sick Children (CA) 2013-06-05 — — EP disclosed
WO-2012018643-A2 COMPOSITIONS FOR PROLIFERATION OF CELLS AND RELATED METHODS THE HOSPITAL FOR SICK CHILDREN (CA) 2012-02-09 — — WO disclosed
US-20110301105-A1 COMPOSITIONS FOR PROLIFERATION OF CELLS AND RELATED METHODS THE HOSPITAL FOR SICK CHILDREN (CA) 2011-12-08 — — US disclosed
EP-1743881-B1 Phenyl-benzyl-ketones RUANE MICHAEL (AU) 2010-12-22 — — EP disclosed
US-20100272790-A1 Methods of Treating Skin TRACIE MARTYN INTERNATIONAL, LLC (US) 2010-10-28 — — US disclosed
US-20100273891-A1 ISOFLAVONE METABOLITES Ruane, Michael (AU) 2010-10-28 — — US disclosed
US-7799955-B2 Isoflavone metabolites Ruane, Michael (AU) 2010-09-21 — — US disclosed
US-7776915-B2 Topical formulations and methods of use TRACIE MARTYN INTERNATIONAL, LLC (US) 2010-08-17 — — US disclosed
US-20090209655-A1 ISOFLAVONE METABOLITES G. J. CONSULTANTS PTY. LTD. (AU) 2009-08-20 — — US disclosed
US-20090209655-A1 ISOFLAVONE METABOLITES G. J. CONSULTANTS PTY. LTD. (AU) 2009-08-20 — — US disclosed
US-20080125481-A1 ISOFLAVONE METABOLITES JOANNOU GEORGE EUSTACE 2008-05-29 — — US disclosed
US-20080125481-A1 ISOFLAVONE METABOLITES JOANNOU GEORGE EUSTACE 2008-05-29 — — US disclosed
EP-1743881-A1 Phenyl-benzyl-ketones G.J. Consultants Pty Ltd (AU) 2007-01-17 — — EP disclosed
US-20060216251-A1 Topical formulations and methods of use TRACIE MARTYN INTERNATIONAL, LLC (US) 2006-09-28 — — US disclosed
US-5574062-A COMPOUNDS HAVE 3-ARYL AND 7-HYDROXY OR -ACYLOXY; USE TO INHIBIT 12-LIPOXYGENASE MORINAGA MILK INDUSTRY CO., LTD. (JP) 1996-11-12 — — US disclosed
US-4814346-A Benzopyrans and use thereof in treating vascular diseases ZYMA SA (CH) 1989-03-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140155961-A1 METHODS OF TREATING SKIN CUTA, LIPA, DLAT ALOX12 62/4885ALOX15 50/4885ALOX15B 39/4885
US-20100272790-A1 Methods of Treating Skin CUTA, LIPA, DLAT ALOX12 62/4885ALOX15 50/4885ALOX15B 39/4885
US-20150150770-A1 METHODS OF TREATING SKIN CUTA, LIPA, DLAT ALOX12 62/4885ALOX15 50/4885ALOX15B 39/4885
US-20100273891-A1 ISOFLAVONE METABOLITES CYP19A1, ESR1, CYP21A2 ALOX12 2643/4885ALOX15 2835/4885ALOX15B 2428/4885
US-20060216251-A1 Topical formulations and methods of use CPT1B, SLC25A20, CPT1A ALOX12 57/4885ALOX15 53/4885ALOX15B 33/4885
US-20140234271-A1 COMPOSITIONS FOR PROLIFERATION OF CELLS AND RELATED METHODS MKI67, KRT18, PROX1 ALOX12 3429/4885ALOX15 3682/4885ALOX15B 3352/4885
US-20090209655-A1 ISOFLAVONE METABOLITES CYP19A1, ESR1, CYP21A2 ALOX12 2643/4885ALOX15 2835/4885ALOX15B 2428/4885
US-20110301105-A1 COMPOSITIONS FOR PROLIFERATION OF CELLS AND RELATED METHODS MKI67, KRT18, PROX1 ALOX12 3429/4885ALOX15 3682/4885ALOX15B 3352/4885
US-20080125481-A1 ISOFLAVONE METABOLITES CYP19A1, ESR1, CYP21A2 ALOX12 2643/4885ALOX15 2835/4885ALOX15B 2428/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.